Members of the US Food and Drug Administration’s Antimicrobial Drugs Advisory Committee were not too worried about whether AstraZeneca PLC and Sanofi’s RSV prevention treatment nirsevimab should be given to infants and neonates, but did question when patients should receive it.
Nirsevimab, which has the provisionally approved trade name Beyfortus, is proposed for prevention of RSV lower respiratory tract disease in...





